Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
November 24, 2008
- Mochida: Forecasts for Both Sales and Profits Revised Upward
November 24, 2008
- Chuikyo Will Continue to Review FPMAJ's Drug Pricing System Reform Proposal: Mr Nagano
November 24, 2008
- Kissei: New Products Make Up for Drop in Sales of Cabaser
November 24, 2008
- Kenporen Generally Satisfied with Improvements of Distribution Business Practices
November 24, 2008
- Nippon Shinyaku: Sales Up 14.1% Due to Licensing of NS-304
November 24, 2008
- REGULATORY NEWS IN BRIEF
November 24, 2008
- Seikagaku: Good Domestic Sales Fail to Make Up for Decreases in Exports
November 24, 2008
- Savings of Up to \18 Tril. Possible by Self Med: NRK Report
November 24, 2008
- MEDICAL DEVICE NEWS IN BRIEF
November 24, 2008
- Zeria: Poor Sales of Healthcare Products Depress Overall Performance
November 24, 2008
- Controversies Continue over On-line Sale of Drugs
November 24, 2008
- Top-Six Wholesalers' Profits Hit by Soft Market Prices
November 24, 2008
- ASKA: Generics Bolster Business
November 24, 2008
- Bayer Confident about Success in the Healthcare Field: Mr Wenning
November 24, 2008
- Losses on Sales Expand to 1.6% for Mediceo Paltac
November 24, 2008
- JCR: Net Profits Expected on a Full-year Basis
November 24, 2008
- Alfresa: Sales Up 16.8%, but Profits Down Sharply
November 24, 2008
- Asahi Kasei Pharma: Famvir Shore Up Sales, Profits
November 24, 2008
- Suzuken: Sales Up 3.8%, Operating Profits Down 29.7%
November 24, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…